miR-765 Acts as a Tumor Promoter and Indicates Poor Prognosis in Non-Small Cell Lung Cancer [Retraction]


We, the Editors and Publisher of OncoTargets and Therapy, have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figure 4 with images from other unrelated articles. Specifically,

- Images from Figure 4A and 4B have been duplicated with images for Figure 4B from Wang C, Wang J, Zhang J, Li Y, Sun Q, Guo F, An X. MicroRNA-623 inhibits tumor progression and is a predictor of poor prognosis of breast cancer. Oncology Letters. 2020;20:386. https://doi.org/10.3892/ol.2020.12249.

The authors did not respond to our queries and were unable to provide an explanation for the duplicated images or provide data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal